DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. (Q38877739)

From Wikidata

Jump to navigation Jump to search

scientific article published on 11 June 2007

Language	Label	Description	Also known as
English	DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity.	scientific article published on 11 June 2007

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17629365%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17629365%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

0 references

Maria Lina Tornesello

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17629365%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17629365%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

author name string

Buonaguro L

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17629365%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Devito C

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17629365%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Schröder U

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17629365%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Wahren B

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17629365%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Buonaguro FM

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17629365%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

language of work or name

0 references

publication date

11 June 2007

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17629365%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17629365%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

25

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17629365%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

32

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17629365%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

5968-5977

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17629365%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

High efficient production of Pr55(gag) virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Virus-like particles: designing an effective AIDS vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

A novel glycoprotein 120 sequence from an HIV type 1 isolate of the A clade identified in North Uganda

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Induction of CD8+ T cells using heterologous prime-boost immunisation strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

The prime-boost strategy: exciting prospects for improved vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Identifying epitopes of HIV-1 that induce protective antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Antibodies: can they protect against HIV infection?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Role of neutralizing antibodies in protective immunity against HIV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

DNA prime/protein boost immunization against HIV clade C: safety and immunogenicity in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

A review of vaccine research and development: the human immunodeficiency virus (HIV).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Comparative analysis of immune responses and cytokine profiles elicited in rabbits by the combined use of recombinant fowlpox viruses, plasmids and virus-like particles in prime-boost vaccination protocols against SHIV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Nasal and parenteral immunizations with diphtheria toxoid using monoglyceride/fatty acid lipid suspensions as adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Immunization with heat-killed Mycobacterium bovis bacille Calmette-Guerin (BCG) in Eurocine L3 adjuvant protects against tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Mapping of B-cell epitopes in rabbits immunised with various gag antigens for the production of HIV-1 gag capture ELISA reagents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

A role for carbohydrates in immune evasion in AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Antiviral antibodies are necessary for control of simian immunodeficiency virus replication

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Role of complement and Fc receptors in the pathogenesis of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Human immunodeficiency virus infection in two cohorts of homosexual men: neutralising sera and association of anti-gag antibody with prognosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

Expression and self-assembly of empty virus-like particles of hepatitis E virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunoglobulin G, plasma cells, and lymphocytes in the murine vagina after vaginal or parenteral immunization with attenuated herpes simplex virus type 2

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.052

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38877739&oldid=1505060569"